Totrial Successfully Helps Yuranos™ Abdominal Aortic Stent Graft System Gain Approval
#News ·2021-11-26 14:10:50
On November 24, 2021, the Yuranos™ abdominal aortic stent graft system independently developed by Xianjian Technology was registered and approved by the National Medical Products Administration (NMPA). This product is used for the endovascular treatment of infrarenal abdominal aortic aneurysms, especially suitable for patients with complex aneurysm morphology. It can improve treatment effects and reduce the risk of surgical complications. Its registration clinical study showed a 100% surgical success rate, efficacy at 12 months post-surgery was superior to the industry average, and no major device-related adverse events.
As a partner of Xianjian Technology, the data team of Huangtu Totrial provided clinical trial data management and online electronic data capture system (EDC) services for this product. Through professional data management and system support, it ensured accurate statistical analysis of clinical trial data, providing important support for the successful approval of Yuranos™.
